Mark Hyman Rapaport

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial
    Mark Hyman Rapaport
    Department of Psychiatry, David Geffen School of Medicine at UCLA, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Clin Psychiatry 70:46-57. 2009
  2. pmc The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Psychiatr Res 45:931-41. 2011
  3. ncbi Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Psychiatry 68:42-6. 2007
  4. ncbi Translating the evidence on atypical depression into clinical practice
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center
    J Clin Psychiatry 68:31-6. 2007
  5. ncbi Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuropsychopharmacology 31:2505-13. 2006
  6. pmc Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia
    Mark H Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuropsychopharmacology 35:428-34. 2010
  7. ncbi Celecoxib augmentation of continuously ill patients with schizophrenia
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles Department of Psychiatry, Geffen School of Medicine, University of California Los Angeles 90045, USA
    Biol Psychiatry 57:1594-6. 2005
  8. ncbi Quality-of-life impairment in depressive and anxiety disorders
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Thalians Mental Health Center C 301, Los Angeles, CA 90048, USA
    Am J Psychiatry 162:1171-8. 2005
  9. ncbi Escitalopram continuation treatment prevents relapse of depressive episodes
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Psychiatry 65:44-9. 2004
  10. ncbi Efficacy of controlled-release paroxetine in the treatment of late-life depression
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, 8730 Alden Dr, Suite C301, Los Angeles, CA 90048, USA
    J Clin Psychiatry 64:1065-74. 2003

Detail Information

Publications26

  1. ncbi Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial
    Mark Hyman Rapaport
    Department of Psychiatry, David Geffen School of Medicine at UCLA, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Clin Psychiatry 70:46-57. 2009
    ..To evaluate the efficacy and tolerability of low daily doses of controlled-release (CR) paroxetine in patients with late-life depression...
  2. pmc The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Psychiatr Res 45:931-41. 2011
    ..MinD was not responsive to either a conventional antidepressant or a nutraceutical, and both compounds were associated with a notable side effects burden. Other treatment approaches for MinD should be investigated...
  3. ncbi Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Psychiatry 68:42-6. 2007
    ..However, MAOIs have been well established as an effective intervention for people with treatment-resistant depression, and transdermal formulations may provide a valuable therapeutic option and eliminate the drug-food interaction...
  4. ncbi Translating the evidence on atypical depression into clinical practice
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center
    J Clin Psychiatry 68:31-6. 2007
    ..Although no tyramine-restricted diet is required for the 6-mg/24-hour patch, a restricted diet is recommended for the higher-dose patches to reduce the risk of hypertensive crisis...
  5. ncbi Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuropsychopharmacology 31:2505-13. 2006
    ..1 and 64.1%, respectively (p < or = 0.05). Open-label risperidone augmentation substantially enhanced response in treatment-resistant patients, but the longer-term benefits of augmentation were not demonstrated in this study...
  6. pmc Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia
    Mark H Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuropsychopharmacology 35:428-34. 2010
    ..We conclude that continuously symptomatic medication-stabilized subjects with schizophrenia have a mitogen-stimulated cytokine expression pattern that is suggestive of ongoing immune activation...
  7. ncbi Celecoxib augmentation of continuously ill patients with schizophrenia
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles Department of Psychiatry, Geffen School of Medicine, University of California Los Angeles 90045, USA
    Biol Psychiatry 57:1594-6. 2005
    ..We hypothesized that celecoxib augmentation therapy would improve psychopathology ratings compared with placebo...
  8. ncbi Quality-of-life impairment in depressive and anxiety disorders
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Thalians Mental Health Center C 301, Los Angeles, CA 90048, USA
    Am J Psychiatry 162:1171-8. 2005
    ....
  9. ncbi Escitalopram continuation treatment prevents relapse of depressive episodes
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Psychiatry 65:44-9. 2004
    ..Current guidelines for antidepressant use recommend 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. This study evaluates the efficacy and safety of continuation escitalopram treatment...
  10. ncbi Efficacy of controlled-release paroxetine in the treatment of late-life depression
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, 8730 Alden Dr, Suite C301, Los Angeles, CA 90048, USA
    J Clin Psychiatry 64:1065-74. 2003
    ..Although the selective serotonin reuptake inhibitors (SSRIs) are the most common pharmacologic intervention for late-life depression, few placebo-controlled trials have assessed the efficacy of SSRIs for this condition...
  11. ncbi Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder
    Lewis L Judd
    Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0603, USA
    Am J Psychiatry 161:1864-71. 2004
    ..Minor depressive disorder is both common and associated with significant psychosocial impairment. This study examined antidepressant treatment efficacy in a large group of patients with minor depressive disorder...
  12. doi A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting
    Waguih William Ishak
    Cedars Sinai Medical Center, 8730 Alden Drive, Thalians W 157, Los Angeles, CA 90048, USA
    Qual Life Res 22:585-96. 2013
    ..We performed a detailed analysis of the interaction between depressive symptom severity, functioning, and QOL in outpatients with MDD in order to better understand QOL impairments in MDD...
  13. ncbi The effects of celecoxib augmentation on cytokine levels in schizophrenia
    Catherine J Bresee
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90045, USA
    Int J Neuropsychopharmacol 9:343-8. 2006
    ..These elevations did not persist by week 8. Overall, celecoxib does not significantly modify cytokine levels in medicated schizophrenia subjects...
  14. doi The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression
    Waguih William Ishak
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
    Harv Rev Psychiatry 19:277-89. 2011
    ..This review will examine the evidence for the impact of each modality, as well as their combination, on QOL in depression...
  15. doi Quality of life: the ultimate outcome measure of interventions in major depressive disorder
    Waguih William Ishak
    University of California, Los Angeles Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA 90048, USA
    Harv Rev Psychiatry 19:229-39. 2011
    ..Patients with major depressive disorder (MDD) have a significantly diminished QOL...
  16. doi Clinical features and functioning of patients with minor depression
    Robert H Howland
    Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Psychother Psychosom 77:384-9. 2008
    ..The two essential features of minor depression are that it has fewer symptoms than major depression and that it is less chronic than dysthymia. This study describes the clinical features and functioning of outpatients with minor depression...
  17. ncbi Translating the evidence on atypical depression into clinical practice
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Clin Psychiatry 68:e11. 2007
    ..A newer MAOI, the transdermal formulation of selegiline, may provide all of the efficacy of the older MAOIs in treating atypical depression without causing as great of adverse events and no diet restrictions...
  18. doi Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study
    Alexander Fan
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Bipolar Disord 14:206-10. 2012
    ..Two previous inpatient trials demonstrated that allopurinol has anti-manic activity. Our objective was to test allopurinol as an adjunct to standard medications in bipolar disorder manic outpatients...
  19. ncbi A descriptive analysis of minor depression
    Mark Hyman Rapaport
    Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, 92037, USA
    Am J Psychiatry 159:637-43. 2002
    ..The authors provide a detailed clinical description of minor depression: its symptoms, level of disability, stability, and relationship to patient and family history of major depressive disorder...
  20. ncbi The role of dopaminergic agents in improving quality of life in major depressive disorder
    Waguih William Ishak
    Department of Psychiatry, Cedars Sinai Medical Center and David Geffen School of Medicine at UCLA, 8730 Alden Drive, Thalians W 157, Los Angeles, CA 90048, USA
    Curr Psychiatry Rep 11:503-8. 2009
    ..Preliminary evidence suggests dopaminergic agents may have a positive effect on QOL for patients with MDD. Prospective, randomized, double-blind, placebo-controlled studies are needed to extend these findings...
  21. ncbi Studies characterizing 60 kda autoantibodies in subjects with schizophrenia
    Xiao Fen Wang
    Department of Psychiatry, Veterans Affairs Medical Center, San Diego, California, USA
    Biol Psychiatry 53:361-75. 2003
    ..We present work identifying and characterizing 60 kDa antigen-antibody interactions...
  22. ncbi Classification and treatment of sub-threshold depression
    Sarah K Rowe
    Cedars Sinai Medical Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90048, USA
    Curr Opin Psychiatry 19:9-13. 2006
    ..The purpose of this review is to evaluate the recent literature on depressive spectrum disorders...
  23. ncbi Helping patients with depression achieve wellness
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, CA, USA
    J Clin Psychiatry 70:e11. 2009
    ..Strategies such as incorporating objective measures into clinical practice and collaborating with patients throughout therapy will increase the likelihood of attaining wellness...
  24. ncbi Beyond acute treatment of depressive disorders
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Clin Psychiatry 70:e21. 2009
    ..By continuously monitoring patients and making modifications when necessary, clinicians can help patients achieve and sustain remission...
  25. pmc Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder
    Lev Gertsik
    California Clinical Trials Medical Group, Glendale, CA 91206, USA
    J Clin Psychopharmacol 32:61-4. 2012
    ..We hypothesized that combination therapy would lead not only to greater efficacy but also to a more rapid onset of therapeutic response...